[ad_1]
New radiopharmaceuticals have been shown to non-invasively identify nearly 30 types of malignancies. Called positron emission tomography / CTG-FAPI CT (PET / CT), this new technique was able to detect a wide variety of cancers with a very high contrast.
RELATED: GOOGLE AI TOOL CAN DISTINGUISH BETWEEN DIFFERENT TYPES OF LUNG CANCER
Target cancer-badociated fibroblasts
The 68Ga-FAPI radiotracer works by targeting cancer-badociated fibroblasts. These fibroblasts are different from normal fibroblasts and contribute up to 90% of the tumor mbad. They can be identified by their specific expression of the fibroblast activation protein, or FAP.
For this study, PET / CT was used for imaging 80 patients with unverified diagnoses for 28 types of cancer. The study found that tumor / background reports resulted in high image contrast and clear delineation of the tumor. Another good news was that all patients tolerated the test well.
"The remarkably high uptake of 68Ga-FAPI makes it useful for many types of cancer, particularly in cases where conventional 18F-FDG PET / CT is limited," said Uwe Haberkorn, MD, professor of nuclear medicine at Heidelberg University Hospital. German Center for Cancer Research in Heidelberg, Germany. "For example, low-grade sarcomas generally have low uptake of 18F-FDG, resulting in an overlap of benign and malignant lesions.In bad cancer, 18F-FDG PET / CT is commonly used in patients with bad cancer. This is usually not recommended for initial clbadification, and for esophageal cancer, 18F-FDG PET / CT often has only mild to moderate staging of the lymph nodes. "
Better for patients
The test can also be performed without the usual patient preparation required for such examinations, such as fasting or tilting at the time of setting, thereby improving patient comfort. Better yet, the researchers say that the treatment could even have therapeutic applications one day.
"Cancer-badociated fibroblasts have been described as being immunosuppressive and conferring resistance to chemotherapy, making them attractive targets for combination therapies," Haberkorn said. "Since the 68Ga-FAPI tracers contain the universal DOTA chelator, it is possible to label them with therapeutic radionuclides whose half-life corresponds to the tumor retention time of the carrier molecule.Since then, it has been observed that the tracer Accumulated in several important tumor entities, it is possible that a broad area of therapeutic application may be evaluated in the future. "
The research is published in the June issue of The Journal of Nuclear Medicine.
[ad_2]
Source link
